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Abstract 19 
Intravesical drug administration is used to deliver chemotherapeutic agents via a catheter to treat 20 
bladder cancer. The major limitation of this treatment is poor retention of the drug in the bladder due to 21 
periodic urine voiding. In this work, maleimide-functionalised PEGylated liposomes (PEG-Mal) were 22 
explored as mucoadhesive vehicles for drug delivery to the urinary bladder. The retention of these 23 
liposomes on freshly excised porcine bladder mucosa in vitro was compared with conventional 24 
liposomes, PEGylated liposomes, two controls (dextran and chitosan), and evaluated through Wash 25 
Out50 (WO50) values. PEG-Mal liposomes exhibited greater retention on mucosal surfaces compared to 26 
other liposomes. The penetration abilities of conventional, PEG-Mal-functionalised and PEGylated 27 
liposomal dispersions with encapsulated fluorescein sodium into the bladder mucosa ex vivo were 28 
assessed using a fluorescence microscopy technique. PEGylated liposomes were found to be more 29 
mucosa-penetrating compared to other liposomes. All liposomes were loaded with fluorescein sodium 30 
salt as a model drug and the in vitro release kinetics was evaluated. Longer drug release was observed 31 
from PEG-Mal liposomes. 32 
 33 
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1. Introduction 37 
Bladder cancer (BC) is caused by uncontrolled growth of tumour cells in the urinary bladder. It 38 
has the 9th highest incidence globally, with an estimated 430,000 newly diagnosed cases in 2012 39 
(Stewart and Wild, 2014). The prevalence of this malignancy of the genitourinary tract tends to 40 
increase with economic development and males are more likely to develop this condition than females 41 
(Torre et al., 2015). The most common type of BC is transitional cell carcinomas that comprise over 42 
90% of tumours, while squamous cell carcinomas and adenocarcinomas represent about 5% and 1% of 43 
the reported cases, respectively. 44 
Intravesical drug delivery (IDD) is a direct administration of therapeutic agents into the bladder 45 
via insertion of a urethral catheter (Au et al., 2001; Malmström, 2003; Kolawole et al., 2017). This 46 
allows localised treatment, minimises adverse effects and improves the exposure of the diseased tissues 47 
to therapeutic agents. Also, the oral route of the drug intake is undesirable in the therapy of BC due to 48 
absorption, metabolism and renal excretion, resulting in poor drug bioavailability in the bladder. 49 
IDD has intrinsic limitations related to the substantial chemotherapy dilution and wash out due to 50 
urinary voiding, low permeability of the urothelium, and intermittent catheterisations (GuhaSarkar and 51 
Banerjee, 2010). Additionally, the procedure is relatively unpleasant for the patients and may cause 52 
inflammatory reactions and infections. To counteract the limitations associated with low drug 53 
permeability, mucoadhesive formulations offer great promise. The ability of mucoadhesive materials to 54 
adhere to the bladder epithelium and withstand wash out effect could improve drug bioavailability by 55 
prolonging the residence in the bladder. Mucoadhesive formulations for IDD must fulfill the following 56 
criteria: the dosage form should have rapid and efficient adhesion to the bladder mucosa; must not 57 
interfere with  the normal physiology of the bladder; and should be able to stay adhered in situ for a 58 
few hours even after urination (Tyagi et al., 2006). 59 
A number of mucoadhesive formulations have been researched, including the use of hydrophilic 60 
polymers of both natural and synthetic type, such as chitosan, carbomers and cellulose derivatives 61 
(Hombach and Bernkop-Schnürch, 2010; Khutoryanskiy, 2011). The adherence of these polymers is 62 
due to the ability to interact with mucin glycoproteins via non-covalent bonds such as hydrogen bonds, 63 
electrostatic interactions and chain entanglements, diffusion and interpenetration (Khutoryanskiy, 64 
2011; Davidovich-Pinhas and Bianco-Peled, 2014). In a comparative study, chitosan was found to 65 
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exhibit greater mucoadhesion to pig vesical mucosa compared to carboxymethylcellulose and 66 
polycarbophyl, thus resulting in a slower drug release and longer residence time (Burjak et al., 2001). 67 
In recent years, various chemical approaches have been used to improve mucoadhesive properties 68 
of polymers by introducing specific functional groups such as thiols (Bernkop-Schnürch, 2005; 69 
Davidovich-Pinhas et al., 2009; Cook et al., 2015), acrylates (Davidovich-Pinhas and Bianco-Peled, 70 
2011; Brannigan and Khutoryanskiy, 2017), and catechols (Kim et al., 2015). Some studies reported 71 
the use of chemically modified mucoadhesive materials for IDD to urinary bladder. Thiol-modified 72 
chitosan nanoparticles (NPs) have been used for IDD in an in vitro study using porcine urinary bladder 73 
(Barthelmes et al., 2011). It was found that chitosan functionalised with thiol groups demonstrated 74 
superior mucoadhesion, greater stability and controlled release compared to the unmodified chitosan 75 
NPs. In a different study, the retention of thiolated chitosan NPs on rat bladder mucosa in vivo was 76 
approximately 170-fold greater compared to the polymer-free fluorescent marker (Barthelmes et al., 77 
2013). Mun et al. (2016) developed and evaluated the retention of thiolated and PEGylated silica NPs 78 
on porcine urinary bladder mucosa in vitro through use of a novel Wash Out50 (WO50) quantitative 79 
method. It was shown that the retention of these NPs on bladder mucosa depended on both their thiol 80 
content and dimensions. 81 
Recently we have demonstrated for the first time that polymers functionalised with maleimide 82 
groups exhibit excellent mucoadhesive properties to conjunctival tissues ex vivo and the ability of these 83 
materials to retain on mucosal tissues was comparable to well-known mucoadhesive chitosan 84 
(Tonglairoum et al., 2016). This excellent mucoadhesive performance of maleimide-functionalised 85 
polymers is due to their ability to form covalent linkages with thiol-groups present in mucins. More 86 
recently, Shtenberg et al. (2017) reported the functionalisation of alginate with maleimide-terminated 87 
polyethyleneglycol to achieve superior mucoadhesive properties towards porcine intestine mucosa. 88 
Liposomes are microscopic vesicles composed of phospholipid bilayers with the size range from 89 
30 nm up to several microns that have attracted a lot of interest over the past four decades as 90 
pharmaceutical carriers. Conventional liposomes and liposomes coated with mucoadhesive polymers 91 
previously were used for transmucosal drug delivery (Sasaki et al., 2013; Berginc et al., 2014; 92 
Adamczak et al., 2017). Some liposome-based formulations were also reported for intravesical drug 93 
delivery (Chuang et al., 2009, 2014; Kawamorita et al., 2016). Recently, Oswald et al. (2016) reported 94 
the preparation and characterisation of maleimide-functionalised liposomes; however they did not 95 
demonstrate any application of these systems for drug delivery. 96 
In this study, we explored the mucoadhesive properties of maleimide-functionalised liposomes 97 
and compared their retention on urinary bladder mucosa with conventional liposomes and PEGylated 98 
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liposomes. We also have studied the physicochemical properties of different liposomes, their 99 
penetration into the bladder mucosa and drug release profiles. 100 
 101 
2. Materials and methods 102 
2.1. Materials 103 
Soybean L-alpha-phosphatidylcholine (PC) was purchased from Alfa Aesar (Heysham, UK). [N-104 
(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanol-amine, 105 
sodium salt] (MPEG2000-DSPE) was a generous gift from Lipoid GmbH (Ludwigshafen, Germany). 106 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] 107 
ammonium salt (PEG2000-DSPE-Mal) was purchased from Avanti Polar Lipids (Alabaster, USA). 108 
Cholesterol (CHO), chitosan (low molecular weight; Mw 62.3 kDa, PDI 3.42 as reported by Symonds 109 
et al (2016)), fluorescein isothiocyanate dextran (FITC-dextran, MW 3000-5000 Da), fluorescein 110 
isothiocyanate (FITC) and fluorescein sodium salt (NaFI) were purchased from Sigma Aldrich 111 
(Gillingham, UK). All other chemicals were of analytical grade and were used as received. 112 
Phosphate-buffered saline (PBS) was composed of 8.0 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4 and 113 
0.24 g KH2PO4 (pH 7.4). The buffer solution was made with deionised water (total volume 1000 mL). 114 
 115 
2.2. Preparation of liposomes 116 
The liposomal formulations containing fixed amounts of PC, CHO and PEGylated lipids at molar 117 
ratios of 10:2:0 and 10:2:3 mM (Table 1) were prepared using thin film hydration and sonication 118 
method (Rangsimawong et al., 2016). In brief, a mixture of PC, CHO and PEGylated lipids dissolved 119 
in chloroform-methanol (2:1, v/v) in test tubes. The organic solvent was evaporated under a stream of 120 
nitrogen and a thin film of lipid was formed inside the test tubes. The test tubes were then placed under 121 
vacuum at least 6 h to remove any residual solvent. Then, solution of NaFI in PBS (pH 7.4) was added 122 
to the dried lipid films to generate hydrated liposome vesicles and the tubes were left for 1 h at room 123 
temperature. The tubes were vortex-mixed vigorously for 30 min and these liposome dispersions were 124 
then sonicated in a sonication bath (FS200b, Decon Laboratories Ltd., UK) for 30 min to reduce the 125 
size of the liposomes. Excess lipids were separated from the vesicle formulations by centrifugation at 126 
14000 rpm (8765 × g) at 4 °C for 30 min. The supernatants were collected and stored in a fridge 127 
overnight prior to characterisation. 128 
 129 
2.3. Synthesis of fluorescently-labelled chitosan 130 
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FITC-chitosan was synthesised according to the procedure described previously (Cook et al., 131 
2011; Symonds et al., 2016). Briefly, 1 g of chitosan was dissolved in 100 mL of acetic acid (0.1 M) 132 
and left stirring overnight. 100 mg of FITC was dissolved in 50 mL of methanol and subsequently was 133 
added to the chitosan solution and stirred for 3 h in the dark at room temperature. The modified 134 
chitosan was then precipitated in 1 L of 0.1 M sodium hydroxide and filtered. The resulting product 135 
was redissolved and purified by dialysis against deionised water in the dark to remove any unreacted 136 
FITC before lyophilisation. FITC-chitosan was kept wrapped in aluminum foil to avoid exposure to 137 
light and stored in a fridge for further use. 138 
 139 
2.4. Particle size and zeta potential analysis 140 
The size of liposomes, their polydispersity index (PDI) and zeta potential values were determined 141 
using dynamic light scattering (DLS) with a Zetasizer Nano-ZS (Malvern Instruments, UK). Each 142 
formulation was diluted 100-fold with ultrapure water. A typical liposome refractive index of 1.45 and 143 
absorbance of 0.1 were used in all measurements. Each sample was analysed three times at 25 °C and 144 
the mean ± standard deviation values were calculated. 145 
 146 
2.5. Transmission electron microscopy 147 
TEM images were generated using a JEOL 2100Plus TEM operating at an acceleration voltage of 148 
200kV. Specimens were prepared by pipetting a drop of liposome suspension diluted with water (about 149 
5 mg/mL) onto a parafilm. A glow-discharged holey carbon film-coated 400-mesh copper grid was 150 
then placed onto the drop with “carbon” side and left in contact with the sample for 1 min. The excess 151 
solution was removed by blotting with a filter paper. The grid was washed by touching its surface with 152 
sample side down on drop of deionised water on parafilm for 1 min and then blotted dry with a filter 153 
paper. A drop of 1% (w/v) uranyl acetate (UA) solution was applied on parafilm and the grid remained 154 
in contact with UA for 30 sec (PEG-Mal liposomes were stained for 5 sec, which provided better 155 
quality of TEM images). The excess stain was removed by dabbing similarly and the sample was left to 156 
dry in air prior to TEM characterisation. 157 
 158 
2.6. Encapsulation efficacy and loading capacity 159 
The lipid nanocarrier dispersion (500 μL) was placed in an ultrafiltration tube using an Amicon® 160 
Ultra-0.5 Ultracel-3 centrifugal filter unit with a molecular weight cutoff of 3 kDa and centrifuged at 4 161 
°C at 14000 rpm (8765 × g) for 60 min. The filtrate was discarded, and 250 μL of PBS was added 162 
before further centrifugation at 4 °C at 14000 rpm (8765 × g) for 40 min. This washing step was 163 
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repeated twice. The NaFI-loaded liposomes in the retentate were then disrupted with 200 μL of 164 
methanol and centrifuged at 4 °C at 14000×g for 10 min. The amount of free NaFI in the supernatants 165 
was quantified using a Varian Cary Eclipse fluorescence spectrometer at excitation and emission = 460 166 
and 512 nm, respectively, and the encapsulation efficiency (%EE) and loading capacity (%LC) were 167 








× 100 170 
 171 
where C is the amount of NaFI entrapped in the liposomes, and Ci is the initial amount of NaFI. 172 
 173 
A calibration curve used to calculate the encapsulation efficacy and loading capacity can be found in 174 
Supplementary Information (Fig S1). 175 
 176 
2.7. Preparation of artificial urine solution 177 
Artificial urine solution was prepared according to the previously reported procedure 178 
(Chutipongtanate and Thongboonkerd, 2010). The following components were dissolved in deionised 179 
water by stirring for 6 h at room temperature, before making the total volume to 2000 mL: urea (24.27 180 
g), uric acid (0.34 g), creatinine (0.90 g), Na3C6H5O7∙2H2O (2.97 g), NaCl (6.34 g), KCl (4.50 g), 181 
NH4Cl (1.61 g), CaCl2∙2H2O (0.67 g), MgSO4∙7H2O (1.00 g), NaHCO3 (0.34 g), Na2C2O4 (0.03 g), 182 
Na2SO4 (2.58 g), NaH2PO4∙H2O (1.00 g), and Na2HPO4 (0.11 g). The artificial urine solution (pH 6.4) 183 
was kept at 37 °C throughout the experiments. 184 
 185 
2.8. In vitro retention studies on porcine urinary bladder 186 
The retention of the liposomes on porcine urinary bladder tissues were determined using a 187 
protocol slightly modified from Mun et al. (2016). Porcine bladder tissues were received from P.C. 188 
Turner Abattoirs (Farnborough, UK), immediately after animal slaughter, packed with dry ice and 189 
transported in a polystyrene container. The tissues were defrosted upon arrival and carefully excised to 190 
yield approximately 2 × 3 cm sections, avoiding contact with the internal mucosa, which were then 191 
used in the experiments. The dissected bladder tissue was mounted on a glass slide with mucosal side 192 
facing upward and rinsed with 3 mL of AU solution. Experiments were performed with the bladder 193 
tissues maintained at 37 °C in an incubator. Aliquots from NaFI-loaded liposome stock solutions were 194 
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withdrawn and diluted 1:1 with PBS (2.3 mg/mL), and aqueous solutions of FITC-chitosan (0.5 mg/mL 195 
in 0.5% acetic acid) and FITC-dextran (0.5 mg/mL in deionised H2O) were prepared. The pH of FITC-196 
chitosan solution was adjusted to pH 6 with 1% NaOH. An aliquot (20 μL) of either NaFI-loaded lipid 197 
nanocarrier dispersions or polymers (controls) was pipetted onto a mucosal surface and irrigated with 198 
AU solution at a flow rate of 2 mL/min using a syringe pump (total washing time was 50 min). 199 
Fluorescence images of whole tissue were taken using a Leica MZ10F stereo-microscope (Leica 200 
Microsystems, UK) with Leica DFC3000G digital camera at 0.8 × magnification with 20 ms exposure 201 
time, fitted with a GFP filter. The microscopy images were then analysed with ImageJ software by 202 
measuring the pixel intensity after each wash. The pixel intensity of the blank samples (bladder mucosa 203 
without test material) were subtracted from each measurement. Each experiment was conducted in 204 
triplicate. 205 
Evaluation of retention of formulations on the mucosa in vitro was quantified through WO50 206 
values, which represent the volume of a biological fluid necessary to wash out 50% of a mucoadhesive 207 
formulation from a substrate (Mun et al., 2016). WO50 values of test materials were calculated via 208 
extrapolation of the wash-off profiles to 50% using polynomial fitting. 209 
 210 
2.9. Mucosal penetration 211 
The mucosal permeation study was carried out as described in Mansfield et al. (2016) using 212 
freshly excised porcine bladder tissues. NaFI-loaded liposome solutions were diluted 1:1 with PBS. 213 
Aliquots (100 μL) of NaFI-loaded liposomes were deposited onto 2 × 2 cm2 ex vivo bladder mucosa, 214 
which were then placed on microscope slides. Deionised water was also pipetted as a blank control. 215 
Samples were left to incubate for 15, 30, 45 and 60 min at 37 °C. Following each time point, tissue 216 
pieces were placed with mucosal layer facing upward into a weighing boat (3.5 × 5.5 cm), half filled 217 
with OCT, a cryoprotective embedding medium. They were then placed on dry ice, before being 218 
completely embedded in OCT to conserve the liposome-loaded mucus membrane. Samples were then 219 
left on dry ice for 3 h. 220 
For sectioning, each sample was mounted onto a 22 mm standard metal sample holder using 221 
OCT, and placed on dry ice for 30 min until completely frozen. Mucosal tissues were cryosectioned 222 
transversely with a standard 189 × 27 × 10 mm blade at 5° to form 25 μm sections, placed onto 223 
Superfrost® Plus charged microscope slides (Thermo Scientific, UK) and left to dry in air for 30 min 224 
before being stored. All sections were cut upwards through the mucosal layer. All specimens were cut 225 
using a Bright 5040 cryostat in a Bright Model PTF freezing chamber at −25 °C (Bright Instrument Co. 226 
Ltd, UK). 227 
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Sections were placed under the Leica MZ10F fluorescence stereo-microscope and all images 228 
taken with 160 ms exposure time through the GFP filter. 10 images were taken for each liposome type 229 
from a separate section of tissue. 230 
ImageJ software was used to evaluate penetration of the liposomes as described by Mansfield et 231 
al. (2016). For each image, the background was subtracted, a line drawn across the mucosal barrier, and 232 
the “plot profile” measured. This was repeated five times at random locations along the mucosal 233 
surface for each image, giving 50 profiles for each sample. These profiles were then evaluated for 234 
penetration of liposomes. This was achieved by measuring the widths of all peaks including the width 235 
of the last peak as the urinary bladder mucosa is heavily folded. The mean values were calculated 236 
following analysis of each profile. To determine penetration into mucosa the values obtained for the 237 
blank tissue at each time point were then subtracted from the other values at the same time point. 238 
 239 
2.10. In vitro release of NaFI from liposomes 240 
The in vitro release of NaFI from liposomes was studied using a dialysis method adopted from 241 
our previous publication (Tonglairoum et al., 2016). In brief, 2 mL of NaFI-loaded liposomes in AU 242 
solution was transferred in a Pur-A-Lyzer™ Maxi 3500 dialysis membrane and immersed in 30 mL of 243 
AU (pH 6.4) that was then shaken at 80 spm for 24 h at 37 °C. At regular intervals, aliquots (5 mL) 244 
were withdrawn from the dialysate and replaced with fresh medium to maintain a constant volume. The 245 
released NaFI was determined using fluorescence spectrometer (λexcitation = 460 and λemission = 512 nm). 246 
Fig 2S (Supplementary Information) shows the calibration curve used in these experiments. All release 247 
experiments were conducted in triplicate. 248 
 249 
2.11. Statistical analysis 250 
Statistical analysis was performed using GraphPad Prism, v5.0. Mean values ± standard 251 
deviations were calculated and assessed for significance using one-way analysis of variance (ANOVA) 252 
followed by Bonferoni post hoc test, where p < 0.05 was fixed as the statistical significance criterion. 253 
 254 
3. Results and discussion 255 
3.1. Preparation and characterisation of liposomes 256 
Conventional, PEG-Mal and PEGylated liposomes were produced using standard thin film 257 
hydration and sonication method and the amount of NaFI was kept equal in all preparations (Table 1). 258 
The average mean diameter of all liposome preparations was ~90 ± 1 nm and the polydispersity index 259 
(PDI) was less than 0.23, which indicates the presence of a homogeneous liposomal population with a 260 
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narrow size distribution (Figure 1). The PDI is a measure of the size distribution and according to the 261 
literature, liposomal formulation is considered to be homogenous if PDI is ≤ 0.30 (Verma et al., 2003). 262 
Vesicles showing their zeta potential of less than -30 mV are believed to have excellent colloidal 263 
stability and have the reduced number of bilayer membranes due to the electrostatic repulsion between 264 
the charges of the same polarity. Furthermore, liposomal formulation with ≤ -30 mV would have higher 265 
entrapment capacity because stronger zeta potential contributes to the increase in the unilamellar 266 
vesicles (Sou, 2011; Kandzija and Khutoryanskiy, 2017). The physicochemical characteristics of 267 
different liposomes are summarised in Table 2. 268 
Many factors influence the encapsulation efficiency (%EE) and loading capacity (%LC) of 269 
liposomes, including partition coefficient of the drug (logP), drug/liposome ratio, lipid composition, 270 
bilayer rigidity, presence of charge, method of preparation, etc (Kulkarni et al., 1995; Nii and Ishii, 271 
2005). According to the literature water-soluble drugs have, however, lower encapsulation in the 272 
liposomes compared to their lipophilic counterparts (Kandzija and Khutoryanskiy, 2017); this depends 273 
on the encapsulated aqueous volume. Since NaFI has a logP = -0.67, we anticipated lower 274 
encapsulation levels (Nii and Ishii, 2005). 275 
NaFI was used as a model drug to demonstrate the potential use of liposomes for the application 276 
in urinary bladder drug delivery. NaFI was loaded into the liposome formulations using standard thin 277 
film method followed by sonication. It was found that conventional liposomes had the highest %EE 278 
(53±6 %), whereas PEG-Mal and PEGylated liposomes exhibited lower %EE of 25±2% and 27±2%, 279 
respectively (Table 2). It should be noted that %EE values determined in the present study are not fully 280 
accurate as it was assumed that all 100 % of lipids used in the formulation were converted into 281 
liposomes.   282 
Transmission electron microscopy (TEM) can be used to evaluate the morphology and fine 283 
structure of liposomes. The freeze-fracture electron microscopy and/or cryo-electron microscopy are 284 
the optimal techniques to study the structure of rapidly frozen biological samples, membranes, proteins, 285 
etc. by TEM, but the preparation of the specimens (cryofixation, fracturation, vitrification and the 286 
following procedure of shading with evaporated platinum or gold, etc.) is complicated and requires 287 
long time (Frederik and Hubert, 2005; Robenek and Severs, 2008; Thompson et al., 2016). In our 288 
experience, negative staining is an easier and faster procedure. During negative staining liposomes are 289 
treated with an electron dense material achieving reasonable contrast. In this work, we used uranyl 290 
acetate that binds the phosphate group of phospholipids and has a limited penetration into the lipidic 291 
bilayer (Harris, 1986). 292 
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TEM microphotographs of the produced liposomes are shown in Figure 2. TEM analysis revealed 293 
the formation of a spherical and small unilamellar membrane for all liposome samples. Also, the 294 
images show a population of homogeneous vesicles. It is also possible to see close bilayer structures 295 
spaced by free internal structure. Furthermore, the negative staining of these liposomes confirms the 296 
results obtained by the DLS analysis (Table 2). This observation is in agreement with the mechanism 297 
that the negative charge on the membrane increases the unilamellar vesicles that have high entrapment 298 
capacity. In addition, unlike conventional liposomes (Figure 2A), formation of aggregates can be 299 
observed in PEG-Mal liposome formulations, which is likely to be due to the hydrophobic nature of 300 
maleimide groups in their structure (Figure 2C). 301 
 302 
3.2. Mucoadhesion studies  303 
The retention properties of NaFI-loaded conventional, PEG-Mal and PEGylated liposomes on 304 
porcine urinary bladder mucosa were assessed using a flow-through method with fluorescent detection 305 
using the methodologies described in our previous publications (Irmukhametova et al., 2011; Storha et 306 
al., 2013; Mun et al., 2016). Figure 3 shows exemplary fluorescent images of the retention of 307 
conventional, PEG-Mal and PEGylated liposomal dispersions as well as two controls (chitosan and 308 
dextran) on urinary bladder mucosa, washed with artificial urine (AU). FITC-chitosan and FITC-309 
dextran were used as a positive and negative controls, respectively (Mun et al., 2016; Tonglairoum et 310 
al., 2016). However, it should be noted that there is a difference between the retention of FITC-311 
modified polymers and retention of free sodium fluorescein released from liposomes. After analysis of 312 
the fluorescent images using ImageJ software, it was established that PEG-Mal liposomes exhibited 313 
very good mucoadhesive properties, comparable to the retention of FITC-chitosan (Figure 4). It was 314 
found that 32% of PEG-Mal liposomes remained on the bladder mucosa even after 50 min of washing 315 
with a total AU volume of 100 mL. Moreover, the percentage retention of PEG-Mal liposomes was 316 
found not to be significantly different from FITC-chitosan (p > 0.05), confirming that PEG-Mal 317 
liposomes can also be adhered well on the bladder mucosa by forming covalent bonds with thiol groups 318 
present in mucin layer of the bladder epithelium. Conventional liposomes had a significantly lower 319 
retention capability compared to PEG-Mal liposomes (p < 0.05). It was found that approximately 18% 320 
of conventional liposomes retained on the bladder epithelial mucosa after 100 mL of washing with AU. 321 
These results confirm the mucoadhesive properties of maleimide-terminated PEGylated liposomes, 322 
which could also be used as a potential mucoadhesive drug carrier. The mechanism of enhanced 323 
mucoadhesion of maleimide-functionalised liposomes includes the formation of covalent linkages 324 
between maleimide groups and thiols present on mucosal surfaces, as shown in Figure 5.   325 
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Mun et al. (2016) have described a novel quantitative method that allows evaluating and 326 
comparing the retention efficiency of liquid formulations on mucosal surfaces through the use of Wash 327 
Out50 (WO50) values, which represent the volume of a biological fluid required to wash out 50% of the 328 
test mucoadhesive material from a substrate. In this work, WO50 values were calculated by analysing 329 
individual wash-off profiles and the results are summarised in Table 2. By comparing these values for 330 
different liposomes used in this study, it is clear that the PEG-Mal liposomes have greater retention on 331 
bladder mucosa (WO50 = 48 mL, R
2=0.9988), compared to conventional liposomes (WO50 = 15 mL, 332 
R2=0.9987), PEGylated liposomes (WO50 = 24 mL, R
2=0.9985) and non-mucoadhesive FITC-dextran 333 
(WO50 = 5 mL, R
2=0.9903), but have weaker mucoadhesive ability than FITC-chitosan (WO50 = 91 334 
mL, R2=0.9970). 335 
 336 
3.3. Penetration into bladder mucosa 337 
In order to assess the penetration properties of NaFI-loaded conventional, PEG-Mal and 338 
PEGylated liposomes through bladder mucosa, fluorescence microscopy was employed. The liposome 339 
solutions were pipetted onto freshly excised porcine urinary bladder mucosa and were left in contact 340 
with the tissues for 15, 30, 45 and 60 minutes and were then frozen and sectioned. Fluorescent images 341 
were then collected and ImageJ software used to evaluate the penetration of liposomes. Figure 6 342 
demonstrates that the PEG liposomes exhibit greater penetration ability (p < 0.05) than conventional 343 
and PEG-Mal counterparts at all time points. The enhanced permeation performance of PEGylated 344 
liposomes into the mucosa, compared to conventional liposomes is in excellent agreement with the 345 
studies of PEGylated nanoparticles on different mucosal barriers (Wang et al., 2008; Mun et al., 2014). 346 
PEG provides stealth properties to liposomes, making them less interactive with biological tissues that 347 
facilitates their deeper penetration. This explains the greater diffusivity of PEGylated liposomes 348 
through mucosal epithelium compared to conventional liposomes. The maleimide-functionalised PEG 349 
liposomes are more mucoadhesive and will therefore form strong covalent bonds with thiols in mucosal 350 
tissue and hence their penetration is slightly retarded (Figure 6). Representative exemplary fluorescent 351 
images of the penetration of different liposomes through porcine bladder mucosa can be found in 352 
Supplementary Information (Figure S3). Better penetration of PEG liposomes into bladder mucosa 353 
could also provide some advantages for intravesical drug delivery; application of penetration enhancers 354 
such as dimethylsuphoxide to facilitate deeper anticancer drug penetration has previously been reported 355 
(Chen et al, 2003).    356 
 357 
3.4. In vitro release from liposomes 358 
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The in vitro release studies for NaFI from conventional, PEG-Mal and PEGylated liposomes 359 
were conducted in AU solution at 37 °C using a dialysis method and the cumulative release profiles are 360 
shown in Figure 7. Conventional liposomes exhibited a rapid release of NaFI, which reaches saturation 361 
after 2 h. PEGylated and PEG-Mal liposomes demonstrated a prolonged release, which reaches 95-100 362 
% after 4 and 8 h, respectively. This difference is clearly related to the presence of PEG on liposomal 363 
surfaces, which makes them more stable. A more prolonged release of a drug from PEG-Mal liposomes 364 
provides an advantage as it will ensure better efficiency and will maintain a therapeutically-relevant 365 
drug concentration in the bladder over a longer period of time following intravesical administration. A 366 
delayed release of NaFI from liposomes could also improve model drug retention on the bladder.  367 
 368 
4. Conclusion 369 
Three liposomal formulations were evaluated in this work for their retention in the urinary 370 
bladder, penetration into the mucosa and drug release in vitro. These formulations were prepared based 371 
on conventional liposomes, PEGylated liposomes and liposomes decorated with maleimide-372 
functionalised PEG. The liposomes with maleimide groups exhibited superior in vitro retention on the 373 
bladder tissue, which is related to their ability to form covalent bonds with thiols present in mucosal 374 
tissue. PEGylated liposomes were found to have a greater ability to penetrate deeper into the mucosal 375 
tissue due to the stealth character of PEG that facilitates mucus-penetrating properties. 376 
 377 
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Figure 1 Size distribution of conventional, PEGylated and PEG-Mal liposomes as determined by DLS 547 
 548 
Figure 2 TEM micrographs of conventional (A), PEGylated (B) and PEG-Mal liposomes (C). Scale 549 
bars are 100 nm for (A) and (B), and 50 nm for (C) 550 
 551 
Figure 3 Exemplar fluorescence images showing retention of FITC-chitosan, PEGylated, PEG-Mal 552 
liposomes, conventional liposomes and FITC-dextran on porcine urinary bladder mucosa washed with 553 
different volumes of AU. Scale bars are 2 μm 554 
 555 
Figure 4 Percentage retention of conventional liposomes, PEGylated, PEG-Mal liposomes, FITC-556 
chitosan and FITC-dextran on porcine urinary bladder mucosa after irrigating with different volumes of 557 
AU. Data are expressed as mean ± standard deviation (n = 3). *Statistically significant difference (p < 558 
0.05) 559 
 560 
Figure 5 Proposed mechanism of bonding between maleimide-functionalised liposomes and mucosal 561 
surfaces 562 
 563 
Figure 6 Penetration of the conventional, PEGylated, PEG-Mal liposomes over 60 mins. Values 564 
represent the mean penetration across 10 separate porcine urinary bladder tissue sections ± standard 565 
deviation 566 
 567 
Figure 7 Cumulative release profile of fluorescein sodium from liposomal formulations. Data expressed 568 
as mean standard deviation (n =3). Insert shows the experimental set-up used in the release studies 569 
 570 
  571 
24 
Table 1 The composition (%) of lipid nanocarrier formulations. 572 
Liposome formulations PC CHO MPEG2000-DSPE PEG2000-DSPE-Mal NaFI 
Conventional 0.773 0.077 - - 0.2 
PEGylated 0.773 0.077 0.075 - 0.2 
PEG-Mal 0.773 0.077 - 0.075 0.2 
PC – Soybean L-alpha-phosphatidylcholine; CHO – Cholesterol; MPEG2000-DSPE – [N-(carbonyl-
methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanol-amine, sodium 
salt]; PEG2000-DSPE-Mal – 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-












%EE %LC WO50, mL 
Conventional 97 ± 1 0.145 -53 ± 1 53 ± 6 12 ± 1 15 
PEGylated 85 ± 1 0.217 -32 ± 2 27 ± 2 6 ± 1 24 
PEG-Mal 86 ± 1 0.224 -37 ± 1 25 ±2 5 ± 1 48 
WO50, volume of AU required to wash out 50% of liquid formulation. Results are given as mean ± 
standard deviation (n = 3) 
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